€3 million investment for GRIP spin-off MimeCure
The University of Groningen spin-off MimeCure, an initiative of GRIP researchers Dr. Luke van der Koog, Prof. Erik Frijlink, Prof. Anika Nagelkerke and Prof. Reinoud Gosens, has raised €3 million to accelerate the development of its therapy for chronic lung diseases. With Addington Investment Group as lead investor and Apsara Investments as co-investor, this marks an important next step towards clinical development.
For the MimeCure team, this is a tremendous milestone. Not only does this investment validate the technology, it also brings the spin-off closer to its goal: developing a therapy that can help restore damaged lung tissue.
This next phase will enable MimeCure to complete its preclinical studies and prepare for first-in-human trials.
Back row, from left to right: Patrick van Eerden (CFO Addington), Arthur Nederlof (CEO Addington), Prof. Anika Nagelkerke (UG), Prof. Reinoud Gosens (UG), Prof. Erik Frijlink (Director MimeCure), Otto Jan van Diepen (Director Apsara).
Front row, from left to right: Ad Nederlof (founder of Addington Investment Group) and Dr. Luke van der Koog (CEO MimeCure).
Lead investor: Addington Investment Group (https://www.addington.nl/)
Co-investor: Apsara Investments (https://www.linkedin.com/company/apsara-investments-pte-ltd/)
More news
-
-
15 September 2025
Successful visit to the UG by Rector of Institut Teknologi Bandung
-